Skip to main content
Clinical Trials/NCT05816902
NCT05816902
Completed
Not Applicable

Development and Validation of an Artificial Intelligence Prediction Model and a Survival Risk Stratification for Lung Metastasis in Colorectal Cancer From Highly Imbalanced Data

Peking Union Medical College0 sites2,779 target enrollmentJanuary 1, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
Peking Union Medical College
Enrollment
2779
Primary Endpoint
lung metastasis
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Background:

To assist clinicians with diagnosis and optimal treatment decision-making, we attempted to develop and validate an artificial intelligence prediction model for lung metastasis (LM) in colorectal cancer (CRC) patients.

Method:

The clinicopathological characteristics of 46037 CRC patients from the Surveillance, Epidemiology, and End Results (SEER) database and 2779 CRC patients from a multi-center external validation set were collected retrospectively. After feature selection by univariate and multivariate analyses, six machine learning (ML) models, including logistic regression, K-nearest neighbor, support vector machine, decision tree, random forest, and balanced random forest (BRF), were developed and validated for the LM prediction. The optimization model with best performance was compared to the clinical predictor. In addition, stratified LM patients by risk score were utilized for survival analysis.

Registry
clinicaltrials.gov
Start Date
January 1, 2016
End Date
December 31, 2020
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Peking Union Medical College
Responsible Party
Principal Investigator
Principal Investigator

Xishan Wang

the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College

Peking Union Medical College

Eligibility Criteria

Inclusion Criteria

  • patients with pathologic confirmation of a primary CRC diagnosis

Exclusion Criteria

  • (1) patients with multiple primary cancers or other malignancies; (2) patients identified via autopsy or death certificate; and (3) patients with uncertain clinical data values

Outcomes

Primary Outcomes

lung metastasis

Time Frame: through study completion, an average of 3 month

diagnosed with lung metastasis

Similar Trials